Andrew Oakley has joined Tokyo-based pharmaceutical firm Sosei as chief financial officer, succeeding Hidetoshi Torami.
Oakley brings a varied corporate finance career to the firm, most recently having served as chief financial officer of Vectura Group.
Prior to this, he held the same title at several other biotech companies, including Actelion and Novimmune.
Peter Bains, chief executive officer of Sosei, said: “Andrew brings a wealth of global corporate finance experience, expertise and leadership with a particularly strong focus in the biotechnology sector.
“I am delighted to welcome him to Sosei as our new chief financial officer and look forward to working with Andrew in the coming years as we seek to build Sosei into a global presence.”